Giovanni Faccia
Interventional Pain Medicine · Columbia, TNNPI 1952396384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 28.8% of the total. Reporting peaked in 2023 at $383 and has fallen 83.9% since, to $62 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in TN, where the typical reported total is $5,250.
Across 71 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$371
- AbbVie$128
- Collegium Pharmaceutical, Inc.$90
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$90
- Gilead$80
- Pfizer$63
- plus $463 from 19 others
What the payments were for
- Food & beverage$1,285100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $371 |
| AbbVie | 7 | $128 |
| Collegium Pharmaceutical, Inc. | 3 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $90 |
| Gilead | 3 | $80 |
| Pfizer | 1 | $63 |
| Amgen | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Alkermes, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $29 |
| Braeburn Inc. | 1 | $25 |
| Bioxcel Therapeutics, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
| Novartis | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Shionogi Inc | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Kaleo, Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $13 |
| USWM, LLC | 1 | $13 |
| GSK | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
How this compares
$1,285 in reported general payments places this provider in the 25th percentile of 41 interventional pain medicine providers in Tennessee.
See all interventional pain medicine providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 119 | $2,081 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 80 | $1,758 |
| Naloxone Hcl | 26 | $1,584 |
| Gabapentin | 71 | $521 |
| Oxycodone Hcl | 34 | $402 |
| Pregabalin | 27 | $331 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $273 |
| Tizanidine Hcl | 16 | $98 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Columbia
- Madhu YelameliColumbia$12K
- Kenneth SykesColumbia$1K
- William NewtonWinchester$225K
- Ryan BearerWinchester$35K
- Michael WilkinsonJohnson City$35K
- Jacob MillsMountain Home$24K
- Matthew KangasMemphis$22K
- Matthew RupertFranklin$17K
- Adolfo CuadraKnoxville$15K
- Cameron ShawverJohnson City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.